AstraZeneca's Saphnelo (anifrolumab) received FDA approval on April 27, 2026, for self-administration via a new autoinjector, enhancing treatment options for adult patients with systemic lupus erythematosus. This first-in-class treatment has successfully shown to significantly reduce disease activity during trials.